X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Silvana Lanzalone

Silvana Lanzalone is a clinician working in Clinical Development – Oncology at Pfizer. She has led clinical trials of a variety of new treatments in different indications and currently, she is the lead clinician on the TALAPRO3 study for men with metastatic Castrate Sensitive Prostate Cancer (mCSPC). She specializes in late phase clinical development and has over 30 years of experience in clinical research. She has contributed to many publications in medical journals on oncology clinical trials and study medications. She earned her degree in Biological Sciences at the University of Milan.